OGEN Profile
Oragenics, Inc., headquartered in Tampa, Florida, is a biopharmaceutical company specializing in the development of innovative treatments and vaccines for infectious diseases. Established in 1996, the company is focused on advancing its portfolio of drug candidates designed to address unmet medical needs. Oragenics' pipeline includes several promising candidates aimed at tackling various health challenges, particularly in the realm of infectious diseases and weight management.
The company's notable product candidates include NT-CoV2-1 and Terra CoV-2, both targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). NT-CoV2-1 is an intranasal vaccine candidate intended to induce immunity against COVID-19 through nasal administration, while Terra CoV-2 is an intramuscular vaccine candidate designed for broader immunization. These vaccines represent Oragenics' commitment to addressing global health crises and contributing to the fight against COVID-19.
In addition to its COVID-19 vaccine candidates, Oragenics is developing LPT3-04, a novel weight loss therapy, and SMaRT Replacement Therapy, a topical treatment aimed at preventing dental caries. LPT3-04 is designed to address obesity by leveraging innovative approaches in drug development, whereas SMaRT Replacement Therapy seeks to improve dental health outcomes through advanced topical treatments.
Oragenics has established strategic partnerships to advance its research and commercialization efforts. This includes a licensing agreement with Noachis Terra Inc. for the use of pre-fusion coronavirus spike proteins and a collaboration with Precigen, Inc. and ILH Holdings, Inc. for the development of MU1140 and related homologs. These partnerships enhance Oragenics' capabilities and accelerate the development of its therapeutic candidates. With a focus on cutting-edge research and strategic collaborations, Oragenics continues to drive innovation in the biopharmaceutical sector.
|
